dual oncolytic virus therapy/anti-CD3/anti-trop-2 bispecific T-cell engager (Calidi Biotherapeutics)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug Namedual oncolytic virus therapy/anti-CD3/anti-trop-2 bispecific T-cell engager (Calidi Biotherapeutics)
Drug Alias NameN/A
ClassificationBiologics > Oncolytic virus
Mechanisms of ActionTumor-associated calcium signal transducer 2 modulatorsT cell surface glycoprotein CD3 modulatorsT lymphocytes stimulants +[4] 
TargetsTumor-associated calcium signal transducer 2T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCalidi Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCalidi Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A